Online inquiry

IVTScrip™ mRNA-Anti-F, MEDI-524(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ11322MR)

This product GTTS-WQ11322MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets F gene. The antibody can be applied in Respiratory Syncytial Virus (RSV) infection research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Humanized
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
UniProt ID P03420
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-F, MEDI-524(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ11322MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ6918MR IVTScrip™ mRNA-Anti-Alkaline phosphatase substitute, ENB-0040(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ENB-0040
GTTS-WQ5059MR IVTScrip™ mRNA-Anti-C5, CaCP-29(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA CaCP-29
GTTS-WQ3565MR IVTScrip™ mRNA-Anti-LYPD3, BAY 1112623(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA BAY 1112623
GTTS-WQ3276MR IVTScrip™ mRNA-Anti-alpha toxin&<br />lukE, ASN-1(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA ASN-1
GTTS-WQ4102MR IVTScrip™ mRNA-Anti-oxLDL, BI-204(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA BI-204
GTTS-WQ5475MR IVTScrip™ mRNA-Anti-tcdB, CDB-1(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA CDB-1
GTTS-WQ516MR IVTScrip™ mRNA-Anti-CD40, 4D11(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA 4D11
GTTS-WQ8016MR IVTScrip™ mRNA-Anti-CD52, GZ-402668(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA GZ-402668
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW